Skip to main content

Kynam Capital Management, LP

13F filer · CIK 0001907884
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.81BU.S. long equity reported on 13F
Positions324 new · 8 closed
Net flow last quarter+$12.8MBuys minus sells
Top 10 positions weight72.7%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202632 positions
CLDXCelldex Therapeutics, Inc.$198M10.95%6.78%-8.9%Q4 2021
SNDXSyndax Pharmaceuticals Inc$176M9.73%9.03%Not reportedQ4 2021
PCVXVaxcyte, Inc.$170M9.39%2.02%Not reportedQ4 2021
COGTCogent Biosciences, Inc.$142M7.84%2.14%-9.2%Q4 2021
VERAVera Therapeutics, Inc.$124M6.85%4.03%-15.0%Q4 2021
VRDNViridian Therapeutics, Inc.\DE$119M6.55%5.70%+175.6%Q4 2021
TVTXTravere Therapeutics, Inc.$114M6.28%2.12%+27.5%Q4 2021
BEAMBeam Therapeutics Inc.$97.5M5.39%2.75%-22.9%Q3 2024
URGNUroGen Pharma Ltd.$89.6M4.95%4.98%+8.3%Q1 2025
LEGNLegend Biotech Corp$86.7M4.79%0.81%+90.4%Q1 2025
CTMXCytomX Therapeutics, Inc.$81.4M4.50%9.97%+44.6%Q2 2025
RLAYRelay Therapeutics, Inc.$61.7M3.41%1.51%+131.7%Q4 2024
CGEMCullinan Therapeutics, Inc.$56.7M3.13%4.84%Not reportedQ4 2024
MBXMBX Biosciences, Inc.$51.6M2.85%1.95%Not reportedQ3 2025
IMCRImmunocore Holdings plc$43.7M2.41%2.67%+55.4%Q4 2024
NRIXNurix Therapeutics, Inc.$29M1.60%1.15%Not reportedQ1 2025
STROSutro Biopharma, Inc.$29M1.60%5.26%Not reportedQ4 2022
BCRXBiocryst Pharmaceuticals Inc$25.2M1.39%0.99%-55.6%Q2 2022
PHVSPharvaris N.V.$22.9M1.26%1.01%+3.3%Q3 2025
SMMTSummit Therapeutics Inc.$17.5M0.97%0.15%NewQ2 2026
PRLDPrelude Therapeutics Inc$12.9M0.71%3.03%+51.7%Q4 2025
INSMINSMED Inc$10.7M0.59%0.05%NewQ2 2026
BNRBurning Rock Biotech Ltd$10.5M0.58%49.48%+0.9%Q4 2021
GERNGeron Corp$8.75M0.48%1.07%Not reportedQ1 2025
AMRNAmarin Corp Plc\uk$8.5M0.47%0.13%+12.8%Q4 2021
ALECAlector, Inc.$7.66M0.42%3.41%+90.4%Q4 2025
PBLSParabilis Medicines, Inc.$6.84M0.38%0.21%NewQ2 2026
CRBUCaribou Biosciences, Inc.$4.41M0.24%2.36%Not reportedQ3 2023
PRQRProQR Therapeutics N.V.$2.91M0.16%1.49%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$996K0.06%0.13%-51.6%Q1 2026
ENGNenGene Therapeutics Inc.$792K0.04%0.68%-66.3%Q3 2024
TRAWTraws Pharma, Inc.$71.2K0.00%0.55%NewQ2 2026
Q1 2026Reported May 15, 202636 positions
SNDXSyndax Pharmaceuticals Inc$188M11.60%9.09%Not reportedQ4 2021
CLDXCelldex Therapeutics, Inc.$185M11.43%8.77%-1.7%Q4 2021
PCVXVaxcyte, Inc.$170M10.48%2.03%Not reportedQ4 2021
COGTCogent Biosciences, Inc.$155M9.59%2.36%-34.5%Q4 2021
VERAVera Therapeutics, Inc.$137M8.43%5.32%-1.0%Q4 2021
BEAMBeam Therapeutics Inc.$87.7M5.41%3.58%+50.9%Q3 2024
CTMXCytomX Therapeutics, Inc.$70.6M4.35%8.82%+67.4%Q2 2025
BCRXBiocryst Pharmaceuticals Inc$54.1M3.34%2.24%-39.4%Q2 2022
TVTXTravere Therapeutics, Inc.$46.6M2.88%1.70%+203.0%Q4 2021
VRDNViridian Therapeutics, Inc.\DE$45.8M2.83%2.29%+59.2%Q4 2021
CGEMCullinan Therapeutics, Inc.$44.3M2.73%5.07%Not reportedQ4 2024
URGNUroGen Pharma Ltd.$40.4M2.49%4.61%Not reportedQ1 2025
KALVKalVista Pharmaceuticals, Inc.$36.7M2.26%3.55%+0.6%Q3 2025
APLSApellis Pharmaceuticals, Inc.$33.2M2.05%0.64%-9.2%Q4 2022
LEGNLegend Biotech Corp$28.5M1.76%0.43%Not reportedQ1 2025
MBXMBX Biosciences, Inc.$27.9M1.72%1.97%Not reportedQ3 2025
IMCRImmunocore Holdings plc$26.7M1.65%1.74%+3.3%Q4 2024
STROSutro Biopharma, Inc.$21.7M1.34%5.27%+81.9%Q4 2022
BNRBurning Rock Biotech Ltd$19.8M1.22%49.04%+23.4%Q4 2021
SLNOSoleno Therapeutics Inc$18.7M1.16%1.08%NewQ1 2026
NRIXNurix Therapeutics, Inc.$18.5M1.14%1.16%-39.4%Q1 2025
PHVSPharvaris N.V.$18.1M1.12%0.98%Not reportedQ3 2025
EVMNEvommune, Inc.$14.4M0.89%1.74%+237.2%Q4 2025
RLAYRelay Therapeutics, Inc.$14.2M0.87%0.75%Not reportedQ4 2024
GERNGeron Corp$10.2M0.63%1.07%+97.8%Q1 2025
ENGNenGene Therapeutics Inc.$9.24M0.57%2.03%-9.1%Q3 2024
DSGNDesign Therapeutics, Inc.$8.35M0.51%1.26%Not reportedQ1 2025
WVEWave Life Sciences, Inc.$7M0.43%0.50%-55.5%Q4 2021
CLYMClimb Bio, Inc.$6.87M0.42%2.10%-2.4%Q4 2024
AMRNAmarin Corp Plc\uk$6.83M0.42%0.11%+21.4%Q4 2021
BHVNBiohaven Ltd.$5.95M0.37%0.47%Not reportedQ4 2025
PRLDPrelude Therapeutics Inc$5.45M0.34%2.53%+101.9%Q4 2025
CRBUCaribou Biosciences, Inc.$4.76M0.29%2.58%Not reportedQ3 2023
ALECAlector, Inc.$4.3M0.27%1.80%Not reportedQ4 2025
PRQRProQR Therapeutics N.V.$2.54M0.16%1.49%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$980K0.06%0.27%NewQ1 2026
Q4 2025Reported Feb 17, 202635 positions
COGTCogent Biosciences, Inc.$219M13.99%3.83%-21.8%Q4 2021
VERAVera Therapeutics, Inc.$174M11.11%5.37%-14.8%Q4 2021
SNDXSyndax Pharmaceuticals Inc$169M10.81%9.21%-5.5%Q4 2021
CLDXCelldex Therapeutics, Inc.$161M10.31%8.93%-2.6%Q4 2021
PCVXVaxcyte, Inc.$135M8.61%2.23%-4.9%Q4 2021
BCRXBiocryst Pharmaceuticals Inc$73.1M4.67%4.40%-0.3%Q2 2022
BEAMBeam Therapeutics Inc.$67.6M4.32%2.40%-3.1%Q3 2024
VRDNViridian Therapeutics, Inc.\DE$45.8M2.92%1.44%-66.8%Q4 2021
TYRATyra Biosciences, Inc.$41.1M2.63%2.91%-32.9%Q4 2023
CGONCG Oncology, Inc.$39.3M2.51%1.17%-52.8%Q2 2024
CTMXCytomX Therapeutics, Inc.$38.2M2.44%5.27%+145.9%Q2 2025
NRIXNurix Therapeutics, Inc.$37.4M2.39%1.94%-9.1%Q1 2025
WVEWave Life Sciences, Inc.$36.9M2.36%1.16%-52.4%Q4 2021
CGEMCullinan Therapeutics, Inc.$32.2M2.06%5.17%+35.3%Q4 2024
IMCRImmunocore Holdings plc$29.7M1.90%1.69%-15.1%Q4 2024
MBXMBX Biosciences, Inc.$29.5M1.88%2.08%-53.3%Q3 2025
KALVKalVista Pharmaceuticals, Inc.$29.2M1.87%3.56%+198.8%Q3 2025
APLSApellis Pharmaceuticals, Inc.$22.8M1.46%0.72%+12.4%Q4 2022
DVAXDynavax Technologies Corp$21.2M1.35%1.17%-35.9%Q3 2023
BNRBurning Rock Biotech Ltd$20M1.28%39.75%Not reportedQ4 2021
TVTXTravere Therapeutics, Inc.$19.8M1.26%0.57%-45.5%Q4 2021
PHVSPharvaris N.V.$17.8M1.14%0.98%-5.1%Q3 2025
ENGNenGene Therapeutics Inc.$13.5M0.86%2.23%-70.1%Q3 2024
RLAYRelay Therapeutics, Inc.$12M0.77%0.82%-50.7%Q4 2024
BHVNBiohaven Ltd.$7.94M0.51%0.53%NewQ4 2025
DSGNDesign Therapeutics, Inc.$7.36M0.47%1.30%-23.8%Q1 2025
STROSutro Biopharma, Inc.$5.55M0.35%5.59%-5.7%Q4 2022
AMRNAmarin Corp Plc\uk$5.43M0.35%0.09%-32.4%Q4 2021
GERNGeron Corp$4.56M0.29%0.54%Not reportedQ1 2025
CLYMClimb Bio, Inc.$4.11M0.26%2.15%Not reportedQ4 2024
CRBUCaribou Biosciences, Inc.$3.98M0.25%2.63%-18.4%Q3 2023
EVMNEvommune, Inc.$3.18M0.20%0.59%NewQ4 2025
PRQRProQR Therapeutics N.V.$3.16M0.20%1.49%-5.0%Q4 2024
ALECAlector, Inc.$3.12M0.20%1.81%NewQ4 2025
PRLDPrelude Therapeutics Inc$2.29M0.15%1.25%NewQ4 2025
Q3 2025Reported Nov 14, 202535 positions
CLDXCelldex Therapeutics, Inc.$158M11.75%9.18%Not reportedQ4 2021
SNDXSyndax Pharmaceuticals Inc$131M9.76%9.80%Not reportedQ4 2021
VERAVera Therapeutics, Inc.$117M8.71%6.31%+17.5%Q4 2021
COGTCogent Biosciences, Inc.$113M8.43%5.64%-7.1%Q4 2021
PCVXVaxcyte, Inc.$111M8.24%2.36%Not reportedQ4 2021
VRDNViridian Therapeutics, Inc.\DE$95.6M7.11%5.38%Not reportedQ4 2021
CGONCG Oncology, Inc.$80.8M6.01%2.56%-18.4%Q2 2024
BCRXBiocryst Pharmaceuticals Inc$71.3M5.31%4.46%+11.0%Q2 2022
BEAMBeam Therapeutics Inc.$61.1M4.55%2.48%+4.1%Q3 2024
IMCRImmunocore Holdings plc$36.7M2.73%2.00%+3.4%Q4 2024
MBXMBX Biosciences, Inc.$35M2.61%4.47%NewQ3 2025
ENGNenGene Therapeutics Inc.$34.1M2.54%9.76%Not reportedQ3 2024
WVEWave Life Sciences, Inc.$33.4M2.49%2.84%Not reportedQ4 2021
TYRATyra Biosciences, Inc.$32.6M2.43%4.37%Not reportedQ4 2023
TVTXTravere Therapeutics, Inc.$22.7M1.69%1.06%-38.4%Q4 2021
DVAXDynavax Technologies Corp$21.3M1.59%1.83%Not reportedQ3 2023
NRIXNurix Therapeutics, Inc.$20M1.49%2.82%+84.8%Q1 2025
UTHRUNITED THERAPEUTICS Corp$20M1.49%0.16%Not reportedQ3 2022
APLSApellis Pharmaceuticals, Inc.$18.3M1.36%0.64%Not reportedQ4 2022
PHVSPharvaris N.V.$16.8M1.25%1.24%NewQ3 2025
RLAYRelay Therapeutics, Inc.$15.1M1.12%1.67%Not reportedQ4 2024
CGEMCullinan Therapeutics, Inc.$13.7M1.02%3.90%+9.8%Q4 2024
CTMXCytomX Therapeutics, Inc.$11.6M0.87%2.21%+69.3%Q2 2025
AMRNAmarin Corp Plc\uk$9.44M0.70%0.14%Not reportedQ4 2021
BNRBurning Rock Biotech Ltd$8.61M0.64%39.75%Not reportedQ4 2021
DSGNDesign Therapeutics, Inc.$7.75M0.58%1.81%Not reportedQ1 2025
KALVKalVista Pharmaceuticals, Inc.$7.38M0.55%1.20%NewQ3 2025
IRWDIronwood Pharmaceuticals Inc$7.16M0.53%3.36%Not reportedQ1 2024
CRBUCaribou Biosciences, Inc.$7.15M0.53%3.28%Not reportedQ3 2023
URGNUroGen Pharma Ltd.$6.94M0.52%0.60%-57.0%Q1 2025
GERNGeron Corp$4.74M0.35%0.54%Not reportedQ1 2025
STROSutro Biopharma, Inc.$4.42M0.33%5.98%Not reportedQ4 2022
EWTXEdgewise Therapeutics, Inc.$4.12M0.31%0.24%Not reportedQ2 2025
PRQRProQR Therapeutics N.V.$3.51M0.26%1.57%Not reportedQ4 2024
CLYMClimb Bio, Inc.$2.07M0.15%1.51%Not reportedQ4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.